Title :

Outcomes following second allogeneic haematopoietic cell transplantation in patients with myelofibrosis: a retrospective study of the chronic malignancies working party of ebmt

Author(s) :

Nabergoj, Mitja [Auteur]
Mauff, Katya [Auteur]
Robin, Marie [Auteur]
Université Paris Diderot - Paris 7 [UPD7]
Krger, Nicolaus [Auteur]
Angelucci, Emanuele [Auteur]
Poire, Xavier [Auteur]
Passweg, Jakob R. [Auteur]
Radujkovic, Aleksandar [Auteur]
Platzbecker, Uwe [Auteur]
Robinson, Stephen [Auteur]
Rambaldi, Alessandro [Auteur]
Petersen, Soren Lykke [Auteur]
Stolzel, Fridrich [Auteur]
Stelljes, Matthias [Auteur]
Ciceri, Fabio [Auteur]
Mayer, Jiri [Auteur]
Ladetto, Marco [Auteur]
De Wreede, Liesbeth C. [Auteur]
Koster, Linda [Auteur]
Hayden, Patrick J. [Auteur]
Czerw, Tomasz [Auteur]
Hernandez-Boluda, Juan Carlos [Auteur]
Mclornan, Donal P. [Auteur]
Chalandon, Yves [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Journal title :

Bone Marrow Transplantation

Abbreviated title :

Bone Marrow Transplant

Volume number :

56

Pages :

1944–1952

Publication date :

2021-08

ISSN :

1476-5365

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Therapeutic management of patients with primary or secondary myelofibrosis (MF) who experience relapse or graft failure following allogeneic haematopoietic cell transplantation (allo-HCT) remains heterogeneous. We ...
Show more >Therapeutic management of patients with primary or secondary myelofibrosis (MF) who experience relapse or graft failure following allogeneic haematopoietic cell transplantation (allo-HCT) remains heterogeneous. We retrospectively analyzed 216 patients undergoing a second allo-HCT for either relapse (56%) or graft failure (31%) between 2010 and 2017. Median age was 57.3 years (range 51-63). The same donor as for the first allo-HCT was chosen in 66 patients (31%) of whom 19 received an HLA-identical sibling donor, whereas a different donor was chosen for 116 patients (54%). Median follow-up was 40 months. Three-year overall survival (OS) and relapse-free survival (RFS) were 42% and 39%, respectively. Three-year non-relapse mortality (NRM) and relapse rates were 36% and 25%, respectively. Grade II-IV and III-IV acute GVHD occurred in 25% and 11% of patients, respectively, and the 3-year incidence of chronic GVHD was 33% including 14% for extensive grade. Graft-failure incidence at 1 year was 14%. In conclusion, our data suggest that a second allo-HCT is a potential option for patients failing first allo-HCT for MF albeit careful patient assessment is fundamental to identify individual patients who could benefit from this approach.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

CHU Lille
Inserm
Université de Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Submission date :

2021-07-06T12:44:28Z
2024-01-22T09:36:01Z